In GBM, the combination of ipilimumab and bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), has been tested in 20 patients and demonstrated a 31% partial response rate with adverse events in 2 patients (Carter et al., 2016). The gene discussed is VEGFA; the disease is glioblastoma.